Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic

Relevance. COVID-19 pandemic currently has a significant negative impact on the treatment of patients with oncological pathology, including patients with classic Hodgkin lymphoma. Generalized data on publications on the impact of concomitant pathology on the severity of infection show a significant...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Irina V. Poddubnaya, Elena A. Baryakh, Vladimir I. Vorobyev, E. A. Demina, Nikolay V. Zhukov, K. D. Kaplanov, T. S. Konstantinova, Dmitry V. Motorin, V. V. Ptushkin, Vladislav O. Sarzhevsky, G. S. Tumyan
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2020
Materias:	hodgkin lymphoma covid-19 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/2004cdd4f9c2412697204e9448c718ca
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2004cdd4f9c2412697204e9448c718ca
record_format	dspace
spelling	oai:doaj.org-article:2004cdd4f9c2412697204e9448c718ca2021-11-30T17:03:34ZTherapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic1815-14341815-144210.26442/18151434.2020.2.200206https://doaj.org/article/2004cdd4f9c2412697204e9448c718ca2020-06-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/34878/23270https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Relevance. COVID-19 pandemic currently has a significant negative impact on the treatment of patients with oncological pathology, including patients with classic Hodgkin lymphoma. Generalized data on publications on the impact of concomitant pathology on the severity of infection show a significant increase in the risk of death from infection in male patients, aged 60 years, with the presence of 3 concomitant diseases, among which particularly negative role is played by diseases of the cardiovascular system, diabetes, oncology, chronic lung disease, immunodeficiency conditions. Particularly dangerous is the development of COVID-19 infection in an interval of less than 14 days from the course of antitumor therapy. At the same time, patients with Hodgkin lymphoma require immediate treatment, often associated with toxic, immunosuppressive therapy, frequent visits to the clinic, hospitalizations. International communities have not yet developed clear guidelines for the management of patients with Hodgkins lymphoma. Taking into account the understanding that the circulation of coronoviral infection will continue in the population, the Advisory board on the Problems of Hodgkin Lymphoma Therapy in the COVID-19 Pandemic is highly relevant. Aim. To change and adapt current treatment approaches in the current epidemiological environment. Results. The main directions of the impact of the COVID-19 pandemic on the treatment of patients with cancer pathology, including patients with classical Hodgkin lymphoma, were determined, key problems in the treatment of LC during the COVID-19 pandemic were identified, and measures aimed at reducing the risk for patients were developed. Existing approaches to first-line, relapse/refracturing cHL therapy, including salvage therapy, and auto/allo SCT during the COVID-19 pandemic, have been adapted.Irina V. PoddubnayaElena A. BaryakhVladimir I. VorobyevE. A. DeminaNikolay V. ZhukovK. D. KaplanovT. S. KonstantinovaDmitry V. MotorinV. V. PtushkinVladislav O. SarzhevskyG. S. TumyanIP Habib O.N.articlehodgkin lymphomacovid-19Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 22, Iss 2, Pp 52-55 (2020)
institution	DOAJ
collection	DOAJ
language	RU
topic	hodgkin lymphoma covid-19 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	hodgkin lymphoma covid-19 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Irina V. Poddubnaya Elena A. Baryakh Vladimir I. Vorobyev E. A. Demina Nikolay V. Zhukov K. D. Kaplanov T. S. Konstantinova Dmitry V. Motorin V. V. Ptushkin Vladislav O. Sarzhevsky G. S. Tumyan Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic
description	Relevance. COVID-19 pandemic currently has a significant negative impact on the treatment of patients with oncological pathology, including patients with classic Hodgkin lymphoma. Generalized data on publications on the impact of concomitant pathology on the severity of infection show a significant increase in the risk of death from infection in male patients, aged 60 years, with the presence of 3 concomitant diseases, among which particularly negative role is played by diseases of the cardiovascular system, diabetes, oncology, chronic lung disease, immunodeficiency conditions. Particularly dangerous is the development of COVID-19 infection in an interval of less than 14 days from the course of antitumor therapy. At the same time, patients with Hodgkin lymphoma require immediate treatment, often associated with toxic, immunosuppressive therapy, frequent visits to the clinic, hospitalizations. International communities have not yet developed clear guidelines for the management of patients with Hodgkins lymphoma. Taking into account the understanding that the circulation of coronoviral infection will continue in the population, the Advisory board on the Problems of Hodgkin Lymphoma Therapy in the COVID-19 Pandemic is highly relevant. Aim. To change and adapt current treatment approaches in the current epidemiological environment. Results. The main directions of the impact of the COVID-19 pandemic on the treatment of patients with cancer pathology, including patients with classical Hodgkin lymphoma, were determined, key problems in the treatment of LC during the COVID-19 pandemic were identified, and measures aimed at reducing the risk for patients were developed. Existing approaches to first-line, relapse/refracturing cHL therapy, including salvage therapy, and auto/allo SCT during the COVID-19 pandemic, have been adapted.
format	article
author	Irina V. Poddubnaya Elena A. Baryakh Vladimir I. Vorobyev E. A. Demina Nikolay V. Zhukov K. D. Kaplanov T. S. Konstantinova Dmitry V. Motorin V. V. Ptushkin Vladislav O. Sarzhevsky G. S. Tumyan
author_facet	Irina V. Poddubnaya Elena A. Baryakh Vladimir I. Vorobyev E. A. Demina Nikolay V. Zhukov K. D. Kaplanov T. S. Konstantinova Dmitry V. Motorin V. V. Ptushkin Vladislav O. Sarzhevsky G. S. Tumyan
author_sort	Irina V. Poddubnaya
title	Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic
title_short	Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic
title_full	Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic
title_fullStr	Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic
title_full_unstemmed	Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic
title_sort	therapy of hodgkin lymphoma in russia during the covid-19 pandemic
publisher	IP Habib O.N.
publishDate	2020
url	https://doaj.org/article/2004cdd4f9c2412697204e9448c718ca
work_keys_str_mv	AT irinavpoddubnaya therapyofhodgkinlymphomainrussiaduringthecovid19pandemic AT elenaabaryakh therapyofhodgkinlymphomainrussiaduringthecovid19pandemic AT vladimirivorobyev therapyofhodgkinlymphomainrussiaduringthecovid19pandemic AT eademina therapyofhodgkinlymphomainrussiaduringthecovid19pandemic AT nikolayvzhukov therapyofhodgkinlymphomainrussiaduringthecovid19pandemic AT kdkaplanov therapyofhodgkinlymphomainrussiaduringthecovid19pandemic AT tskonstantinova therapyofhodgkinlymphomainrussiaduringthecovid19pandemic AT dmitryvmotorin therapyofhodgkinlymphomainrussiaduringthecovid19pandemic AT vvptushkin therapyofhodgkinlymphomainrussiaduringthecovid19pandemic AT vladislavosarzhevsky therapyofhodgkinlymphomainrussiaduringthecovid19pandemic AT gstumyan therapyofhodgkinlymphomainrussiaduringthecovid19pandemic
_version_	1718406432748994560

Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic

Ejemplares similares